204 related articles for article (PubMed ID: 33116484)
1. Development of Rifapentine-Loaded PLGA-Based Nanoparticles: In vitro Characterisation and in vivo Study in Mice.
Liang Q; Xiang H; Li X; Luo C; Ma X; Zhao W; Chen J; Tian Z; Li X; Song X
Int J Nanomedicine; 2020; 15():7491-7507. PubMed ID: 33116484
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
3. HPMA-PLGA Based Nanoparticles for Effective In Vitro Delivery of Rifampicin.
Rani S; Gothwal A; Pandey PK; Chauhan DS; Pachouri PK; Gupta UD; Gupta U
Pharm Res; 2018 Dec; 36(1):19. PubMed ID: 30511238
[TBL] [Abstract][Full Text] [Related]
4. Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles.
Mustafa S; Devi VK; Pai RS
Drug Deliv Transl Res; 2017 Feb; 7(1):27-36. PubMed ID: 27576453
[TBL] [Abstract][Full Text] [Related]
5. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
[TBL] [Abstract][Full Text] [Related]
6. Development of tetracycline-modified nanoparticles for bone-targeted delivery of anti-tubercular drug.
Liang Q; Zhang P; Zhang L; Luan H; Li X; Xiang H; Jing S; Song X
Front Bioeng Biotechnol; 2023; 11():1207520. PubMed ID: 37635999
[No Abstract] [Full Text] [Related]
7. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization.
Sánchez-López E; Ettcheto M; Egea MA; Espina M; Cano A; Calpena AC; Camins A; Carmona N; Silva AM; Souto EB; García ML
J Nanobiotechnology; 2018 Mar; 16(1):32. PubMed ID: 29587747
[TBL] [Abstract][Full Text] [Related]
8. Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma.
Liu XJ; Li L; Liu XJ; Li Y; Zhao CY; Wang RQ; Zhen YS
Int J Nanomedicine; 2017; 12():5255-5269. PubMed ID: 28769562
[TBL] [Abstract][Full Text] [Related]
9. Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages.
Tukulula M; Gouveia L; Paixao P; Hayeshi R; Naicker B; Dube A
Pharm Res; 2018 Mar; 35(6):111. PubMed ID: 29600438
[TBL] [Abstract][Full Text] [Related]
10. Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: An in vitro-in vivo study.
Gajbhiye KR; Gajbhiye V; Siddiqui IA; Pilla S; Soni V
Sci Rep; 2017 Sep; 7(1):11086. PubMed ID: 28894228
[TBL] [Abstract][Full Text] [Related]
11. In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid.
Booysen LL; Kalombo L; Brooks E; Hansen R; Gilliland J; Gruppo V; Lungenhofer P; Semete-Makokotlela B; Swai HS; Kotze AF; Lenaerts A; du Plessis LH
Int J Pharm; 2013 Feb; 444(1-2):10-7. PubMed ID: 23357255
[TBL] [Abstract][Full Text] [Related]
12. Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis.
Andreu V; Larrea A; Rodriguez-Fernandez P; Alfaro S; Gracia B; Lucía A; Usón L; Gomez AC; Mendoza G; Lacoma A; Dominguez J; Prat C; Sebastian V; Ainsa JA; Arruebo M
Nanomedicine (Lond); 2019 Mar; 14(6):707-726. PubMed ID: 30734643
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.
Li Z; Huang H; Huang L; Du L; Sun Y; Duan Y
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28406431
[TBL] [Abstract][Full Text] [Related]
14. Novel PLGA-based nanoparticles for the oral delivery of insulin.
Malathi S; Nandhakumar P; Pandiyan V; Webster TJ; Balasubramanian S
Int J Nanomedicine; 2015; 10():2207-18. PubMed ID: 25848248
[TBL] [Abstract][Full Text] [Related]
15. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.
Bi C; Wang A; Chu Y; Liu S; Mu H; Liu W; Wu Z; Sun K; Li Y
Int J Nanomedicine; 2016; 11():6547-6559. PubMed ID: 27994458
[TBL] [Abstract][Full Text] [Related]
16. Idarubicin-loaded methoxy poly(ethylene glycol)-
Liang B; Li N; Zhang S; Qi A; Feng J; Jing W; Shi C; Ma Z; Gao S
Int J Nanomedicine; 2019; 14():543-556. PubMed ID: 30666113
[TBL] [Abstract][Full Text] [Related]
17. Co-Delivery Anticancer Drug Nanoparticles for Synergistic Therapy Against Lung Cancer Cells.
Shen Y; TanTai J
Drug Des Devel Ther; 2020; 14():4503-4510. PubMed ID: 33122893
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor.
Alam N; Koul M; Mintoo MJ; Khare V; Gupta R; Rawat N; Sharma PR; Singh SK; Mondhe DM; Gupta PN
Biomed Pharmacother; 2017 Nov; 95():856-864. PubMed ID: 28903181
[TBL] [Abstract][Full Text] [Related]
19. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced.
Song X; Wang J; Xu Y; Shao H; Gu J
Colloids Surf B Biointerfaces; 2019 Aug; 180():110-117. PubMed ID: 31030022
[TBL] [Abstract][Full Text] [Related]
20. Preparation, evaluation, and
Pan X; Liu S; Ju L; Xi J; He R; Zhao Y; Zhuang R; Huang J
Drug Dev Ind Pharm; 2020 Nov; 46(11):1889-1897. PubMed ID: 32975456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
